Clinical Trial Update: A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. [Phase 2]

View source ↗

Summary

The Phase 2 study of EDP-938 for respiratory syncytial virus infection in high-risk, non-hospitalized adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• EDP-938 (EDP-938)

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: RSV Infection | Phase 2 | Status: COMPLETED